ARHI/NOEY2 inactivation may be important in breast tumor pathogenesis

Oncology
Hisashi HisatomiNorio Kohno

Abstract

Allelic loss frequently occurs on the short arm of chromosome 1 in human breast carcinoma, suggesting that the ARHI/NOEY2 gene, an imprinted putative tumor suppressor gene, is involved in the pathogenesis of the tumor entity. To clarify the clinical importance of ARHI/NOEY2 mRNA in breast cancer, we studied whether ARHI/NOEY2 inactivation might contribute to tumors arising in the breast. An ARHI/NOEY2 message was detected by real-time PCR analysis in all noncancerous breast tissues, but was not detected in 2 of 26 breast cancer tissue samples. In 10 of 26 breast cancer tissue samples ARHI/NOEY2 mRNA was substantially reduced. ARHI/NOEY2 expression was lost or markedly reduced in 12 of 26 (46.15%) breast cancer tissue samples. In summary, we conclude that decreased ARHI/NOEY2 mRNA expression may play an important role in the pathogenesis of breast cancer.

Citations

Apr 14, 2012·Journal of Gastroenterology and Hepatology·Hai-Ling TangJian-Lin Ren
Jan 6, 2009·Bioscience Hypotheses·K LaiLj Elsas
Jul 6, 2015·Pathology Oncology Research : POR·Chang Jae KimNeung Hwa Park
Oct 19, 2013·Epigenetics : Official Journal of the DNA Methylation Society·Tianjiao LyuWeiwei Feng
Sep 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jan P A BaakEmiel A M Janssen
Jun 2, 2009·The Breast : Official Journal of the European Society of Mastology·Julun YangTao Li
Mar 6, 2018·Cancer Biomarkers : Section a of Disease Markers·Li-Xia ZhongLi-Zhu Lin
Oct 15, 2018·Journal of Cellular Physiology·Xueli LiXiaotong Hu
Apr 4, 2003·International Journal of Cancer. Journal International Du Cancer·Hisashi HisatomiShoji Harada
Apr 1, 2015·Asian Pacific Journal of Cancer Prevention : APJCP·Asfandyar SheikhDalal M Al Tamimi
Mar 1, 2013·Molecular Medicine Reports·Yi-Qun HuJing-Ping Zhou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.